SRPTHealthcare · BiotechnologyThe 24 Wall Street analysts covering Sarepta Therapeutics, Inc. hold a median 12-month price target of $20 — +6.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Sarepta Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (27): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SRPT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +6.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 July 2026 | Piper Sandler | Maintains | Neutral | $23 → $20 |
| 9 July 2026 | Wolfe Research | Upgrade | Outperform | $27 |
| 16 Apr 2026 | HC Wainwright & Co. | Reiterates | Sell | — |
| 26 Mar 2026 | Citigroup | Maintains | Sell | — |
| 26 Mar 2026 | Needham | Reiterates | Underperform | — |
| 19 Mar 2026 | Oppenheimer | Reiterates | Outperform | — |
| 13 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 10 Mar 2026 | Citigroup | Maintains | Sell | — |
| 2 Mar 2026 | HC Wainwright & Co. | Reiterates | Sell | — |
| 27 Feb 2026 | Wells Fargo | Maintains | Overweight | — |
| 27 Jan 2026 | HC Wainwright & Co. | Reiterates | Sell | — |
| 23 Jan 2026 | Wedbush | Maintains | Outperform | — |
| 14 Jan 2026 | HC Wainwright & Co. | Reiterates | Sell | — |
| 9 Dec 2025 | Wedbush | Initiates | Outperform | — |
| 5 Nov 2025 | Barclays | Maintains | Equal-Weight | — |
| 5 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 5 Nov 2025 | Mizuho | Upgrade | Outperform | — |
| 5 Nov 2025 | Wells Fargo | Maintains | Overweight | — |
| 4 Nov 2025 | Baird | Maintains | Neutral | — |
| 30 Oct 2025 | Piper Sandler | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SRPT appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 17% of US stocks
Cheaper than 70% of US stocks
Cheaper than 64% of US stocks
Cheaper than 97% of US stocks
Higher than 8% of US stocks
Higher than 14% of US stocks
Higher than 76% of US stocks
Higher than 69% of US stocks
Higher than 22% of US stocks
Higher than 36% of US stocks
Higher than 39% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Sarepta Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Sarepta beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.
Why it matters — A SRPT watcher would care because the results and updated 2026 guidance signal how Elevidys performance and cost management are shaping the company's financial trajectory.
Sarepta Therapeutics reported second-quarter 2026 total revenue of $401 million, down 34% year over year amid lower ELEVIDYS sales. The company posted GAAP operating income of $13 million and non-GAAP operating income of $86 million, and increased cash and investments by about $197 million to $945 million during the quarter.
Why it matters — SRPT watchers would care because it pairs weaker ELEVIDYS-driven revenue with still-positive operating income and a growing cash position, giving a fuller picture of the quarter's financial health.
Seeking Alpha published the transcript of Sarepta Therapeutics' second-quarter 2026 earnings call. The item is the earnings call transcript itself.
Why it matters — A transcript of the Q2 2026 earnings call gives SRPT watchers direct access to management's own commentary on the quarter.
Sarepta Therapeutics reported Q2 earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.58 per share, and its quarterly revenues also surpassed estimates. This compares with earnings of $2.02 per share in the year-ago quarter.
Why it matters — A SRPT watcher would note that the company beat Wall Street's earnings and revenue expectations for the quarter, even though per-share earnings came in below the prior-year level.
Zacks reports on Sarepta Therapeutics' results for the quarter ended June 2026, noting that the company's top- and bottom-line numbers indicate how the business performed. The article examines how some of its key metrics compare with Wall Street estimates and year-ago values.
Why it matters — An SRPT watcher would care because a review of the key metrics against Wall Street estimates and prior-year figures offers a closer look at how the quarterly performance lines up with expectations.
The 24 Wall Street analysts covering Sarepta Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $5 to $38. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 24 analysts covering Sarepta Therapeutics, Inc., 8 rate it a Buy, 11 a Hold and 5 a Sell. Ticker Nerd's systematic factor model ranks Sarepta Therapeutics, Inc. 72 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Sarepta Therapeutics, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
No one can know that. What the data says: the median 12-month target from 24 analysts implies +6.5% from the last close, and Ticker Nerd's factor model ranks Sarepta Therapeutics, Inc. 72 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Sarepta Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $38 over the next 12 months.
Sarepta Therapeutics, Inc. returned -6.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Sarepta Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing therapies for rare diseases, with a strong emphasis on genetic and neuromuscular disorders.
The most recent item we track (Zacks Investment Research, 6 Aug 2026): "Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated". Sarepta beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.
Sarepta Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing therapies for rare diseases, with a strong emphasis on genetic and neuromuscular disorders. The company’s current portfolio includes approved treatments for Duchenne muscular dystrophy, alongside research programs in RNA-based medicines, gene therapy, and other genetic modalities. Sarepta Therapeutics also advances a broader pipeline for rare muscle and central nervous system diseases, reflecting its specialization in precision medicines for underserved patient populations. Its products and development efforts position the company as a notable participant in the rare-disease therapeutics market, where specialized science and targeted treatments are central to clinical and commercial activity.
CEO Dr. Michael E. Severino M.D. · 835 employees · United States · https://www.sarepta.com